Lipodystrophy and metabolic complications of highly active antiretroviral therapy
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To assess the metabolic drug toxicities of first-line, World Health Organization (WHO)-recommended generic highly active antiretroviral therapy (HAART) regimens, to estimate the prevalence of body fat redistribution and to identify associated risk factors.
Cross-sectional observational study. During 3 month period, 52 HIV infected children (25 on HAART; 27 not on HAART) were assessed. Their sociodemographic, clinical, and immunological data was recorded. Children were examined or the signs of fat redistribution (peripheral lipoatrophy and central lipohypertrophy). Liver function tests, fasting blood sugar, lipid profile, serum amylase, serum lactate, blood pH and bicarbonate levels were done in all patients.
Twenty-two patients were on stavudine and three on zidovudine based HAART. None of the patients ever received any protease inhibitor. There were no cases of clinical or immunological failure. Children on HAART had significantly lower weight for age and body mass index but the mean height for age was similar between study groups. Only two cases of peripheral lipoatrophy were observed. Hypercholesterolemia was observed in four children on HAART but none without therapy. Hypertriglyceridemia was observed in three children on HAART and seven without therapy. Four cases of asymptomatic mild hyperlactatemia were observed. No case of any hyperglycemia or liver impairment was observed.
Metabolic abnormalities and lipodystrophy are emerging complications of HAART in Indian children and needs very close follow up. Future studies with larger sample size and longitudinal model are recommended.
- Carr, A., Samaras, K., Thorsidottir, A., Kaufman, G.R., Chisholm, D.J., Cooper, D.A. (1999) Diagnosis, prediction and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 353: pp. 2093-2099 CrossRef
- Vigouroux, C., Gharakhanian, S., Salhi, Y., Nguyen, T.H., Adda, N., Rozenbaum, W. (1999) Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabet Metab 25: pp. 383-392
- Safrin, S., Grunfeld, C. (1999) Fat distribution and metabolic changes in patients with HIV infection. AIDS 13: pp. 2493-2505 CrossRef
- John, M., Nolan, D., Mallal, S. (2001) Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 6: pp. 9-20
- Chen, D.S., Misra, A., Garg, A. (2002) Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 87: pp. 4845-4856 CrossRef
- Leow, M.K., Addy, C.L., Mantzoros, C.S. (2003) Clinical review 159. Human immunodeficiency virus/highly active antiretroviral therapy associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 88: pp. 1961-1976 CrossRef
- Pujari, S.N., Dravid, A., Naik, E., Bhagat, S., Tash, K., Nadler, J.P. (2005) Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organizationrecommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 39: pp. 199-202
- Saghayam, S., Chaguturu, S.K., Kumarasamy, N., Solomon, S., Mayer, K.H., Wanke, C. (2004) Lipoatrophy is the predominant presentation of HIV-associated lipodystrophy in southern India. Clin Infect Dis 38: pp. 1646-1647 CrossRef
- Amaya, R.A., Kozinetz, C.A., McMeans, A., Schwarzwald, H., Kline, M.W. (2002) Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 21: pp. 405-410 CrossRef
- Bockhorst, J.L., Ksseiry, I., Toye, M., Chipkin, S.R., Stechenberg, B.W., Fisher, D.J., Allen, H.F. (2003) Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pediatr Infect Dis J 22: pp. 463-465 CrossRef
- Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIVinfected children in Europe. AIDS 18: pp. 1443-1451 CrossRef
- Sánchez Torres, A.M., Munoz Muniz, R., Madero, R., Borque, C., García-Miguel, M.J., José Gómez, M.I. (2005) Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 164: pp. 271-276 CrossRef
- Taylor, P., Worrell, C., Steinberg, S.M., Hazra, R., Jankelevich, S., Wood, L.V. (2004) Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitorcontaining, highly active antiretroviral therapy regimens. Pediatrics 114: pp. e235-e242 CrossRef
- Ene, L., Goetghebuer, T., Hainaut, M., Peltier, A., Toppet, V., Levy, J. (2007) Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr 166: pp. 13-21 CrossRef
- Hartman, K., Verweel, G., Groot, R., Hartwig, N.G. (2006) Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 25: pp. 427-431 CrossRef
- Ergun-Longmire, B., Lin-Su, K., Dunn, A.M., Chan, L., Ham, K., Sison, C. (2006) Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus. Endocr Pract 12: pp. 514-521
- Carter, R.J., Wiener, J., Abrams, E.J., Farley, J., Nesheim, S., Palumbo, P. (2006) Perinatal AIDS Collaborative Transmission Study-HIV Follow-up after Perinatal Exposure (PACTS-HOPE) Group. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999–2004: a longitudinal analysis. J Acquir Immune Defic Syndr 41: pp. 453-460 CrossRef
- Solórzano Santos, F., Gochicoa Rangel, L.G., Palacios Saucedo, G., Vázquez Rosales, G., Miranda Novales, M.G. (2006) Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors. Arch Med Res 37: pp. 129-132 CrossRef
- Lapphra, K., Vanprapar, N., Phongsamart, W., Chearskul, P., Chokephaibulkit, K. (2005) Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART). J Med Assoc Thai 88: pp. 956-966
- Beregszaszi, M., Dollfus, C., Levine, M., Faye, A., Deghmoun, S., Bellal, N. (2005) Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIVinfected children. J Acquir Immune Defic Syndr 40: pp. 161-168 CrossRef
- Scaling up Antiretroviral Therapy in Resourcelimited Settings: Treatment Guidelines for a Public Health Approach. World Health Organization, Geneva
- Marshall, W.A., Tanner, J.M. (1970) Variations in pattern of pubertal changes in boys. Arch Dis Child 45: pp. 13-23 CrossRef
- Carr, A., Emery, S., Law, M., Puls, R., Lundgren, J.D., Powderly, W.G. (2003) An objective case definition of lipodystrophy in HIVinfected adults: a case-control study. Lancet 361: pp. 726-735 CrossRef
- Carr, A., Law, M. (2003) An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 33: pp. 571-576 CrossRef
- Lauer, R., Barness, L.A., Clark, R. (1992) Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 89: pp. 525-584
- Divisions of AIDS, National Institute of Allergy and Infectious Diseases. Toxicity table for grading severity of pediatric adverse experiences. April 1994. Available at: http://www.hptn.org/Web%20Documents/Regulatory_Resources.
- Lipodystrophy and metabolic complications of highly active antiretroviral therapy
The Indian Journal of Pediatrics
Volume 76, Issue 10 , pp 1017-1021
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors